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Oncogene activation induces DNA damage re-
sponses and cell senescence. We report a key
role of type I interferons (IFNs) in oncogene-induced
senescence. IFN signaling-deficientmelanocytes ex-
pressing activated Braf do not exhibit senescence
and develop aggressive melanomas. Restoration of
IFNsignaling in IFN-deficientmelanomacells induces
senescence and suppressesmelanoma progression.
Additional data from human melanoma patients and
mouse transplanted tumor models suggest the
importance of non-cell-autonomous IFN signaling.
Inactivation of the IFN pathway is mediated by the
IFN receptor IFNAR1 downregulation that invari-
ably occurs during melanoma development. Mice
harboring an IFNAR1 mutant, which is partially resis-
tant to downregulation, delay melanoma develop-
ment, suppress metastatic disease, and better
respond to BRAF or PD-1 inhibitors. These results
suggest that IFN signaling is an important tumor-sup-
pressive pathway that inhibits melanoma develop-
ment andprogression andargue for targeting IFNAR1
downregulation to prevent metastatic disease and
improve the efficacy of molecularly target and im-
mune-targeted melanoma therapies.INTRODUCTION
Oncogene-induced senescence (OIS) represents an essential
cell-autonomous tumor-suppressive mechanism that protectsThis is an open access article under the CC BY-Ncells harboring damaged genes from malignant transformation
and prevents development of malignant tumors (Campisi and
d’Adda di Fagagna, 2007). Activating mutations in RAS or RAF
genes stimulates the mitogen-activated protein kinase (MAPK)
pathway and triggers an initial burst of cell proliferation, followed
by the onset of OIS (Campisi and d’Adda di Fagagna, 2007;
Kuilman et al., 2010). For example, mutagenic activation of
BRAF and OIS markers are frequently found in benign melano-
cytic hyperplastic lesions (nevi) in humans (Dong et al., 2003;
Pollock et al., 2003). Furthermore, mice expressing BrafV600E
mutant in melanocytes display increased proliferation of these
melanocytes but rarely develop malignant melanoma (Damsky
et al., 2015; Dankort et al., 2009). While senescence is the term
usually reserved for a permanent cell proliferation arrest, addi-
tional genetic and epigenetic alterations can override this perma-
nence (Souroullas and Sharpless, 2015). These additional events
can restore the cycling of a genetically altered cell, leading to
completion of malignant transformation and initiation of malig-
nant tumor development. For melanocytes that harbor BrafV600E
mutation, such events include loss ofPten and hyperactivation of
the phosphatidylinositol 3-kinase (PI3K) pathway (Dankort et al.,
2009) and/or activation of the mTOR pathway (Damsky et al.,
2015).
Activation of DNAdamage responses plays a central role in the
development of OIS (Bartkova et al., 2006; Di Micco et al., 2006).
The DNA-damage-induced production of type I interferons
(IFNs, including IFNa and IFNb) was shown to contribute to the
extent of senescence in cells and tissues harboring persistent
DNA damage (Yu et al., 2015). IFNs are anti-viral cytokines
that bind to their cognate IFNAR1/IFNAR2 receptor to induce
the signal transduction pathway involving Janus kinases and
STAT1/2 proteins and culminating in expression of IFN-stimu-
lated genes, some of which suppress cell proliferation and
survival (reviewed in Platanias, 2005). IFNs can induce cellCell Reports 15, 171–180, April 5, 2016 ª2016 The Authors 171
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senescence (Moiseeva et al., 2006) and, in addition to cell-auton-
omous effects on malignant cells, exert indirect tumor-suppres-
sive functions, such as inhibition of angiogenesis and induction
of anti-tumor immunity (Borden et al., 2007). Based on these ac-
tivities, IFNs remain a standard option in the therapy of a number
of cancers, including melanoma (Kirkwood et al., 2012; Tarhini
et al., 2012).
However, a tumor-suppressive function of IFNs in melanoma
is not fully supported by available data from mice lacking the
Ifnar1 receptor, which is required for all effects of IFNs on cells
(Fuchs, 2013; Piehler et al., 2012; Uze´ et al., 2007). Although
growth of transplanted melanoma tumors was modestly (if at
all) stimulated in Ifnar1/ mice (Bald et al., 2014; Fuertes
et al., 2011; Nu´n˜ez et al., 2012), ablation of Ifnar1 in Hgf-Cdk4
R24C mice did not accelerate development of cutaneous mela-
noma induced by 7,12-dimethylbenz(a)anthracene (Bald et al.,
2014). In addition, hyperactivation of either mTorc1 (Damsky
et al., 2015) or PI3K-Akt (Dankort et al., 2009) pathways in
mice that express BrafV600E mutant in melanocytes could over-
come OIS in Ifnar1+/+ mice that do not harbor any genetic defi-
ciency in the IFN pathway. Furthermore, Ifnar1+/+ animals whose
melanocytes lacked Pten and harbored BrafV600E mutation
developed highly aggressive metastatic melanomas (Dankort
et al., 2009).
Given that the levels of IFNAR1 protein can be rapidly downre-
gulated through a number of phosphorylation-dependent ubiqui-
tination mechanisms (reviewed in Fuchs, 2013), we hypothe-
sized that mobilization of these mechanisms in melanoma may
override the tumor-suppressive role of IFN in this malignancy.
Downregulation of IFNAR1 occurs in response to its ubiquitina-
tion by the SCF-bTrcp2/HOS E3 ubiquitin ligase (Kumar et al.,
2003), which binds to IFNAR1 after its phosphorylation (on
Ser535/539 in human IFNAR1 or Ser526/530 in mouse IFNAR1;
Kumar et al., 2004). This phosphorylation can be induced by
ligands (Zheng et al., 2011b) and additional stimuli, including
inflammation (Bhattacharya et al., 2014). Melanoma cells are
known to upregulate the levels of bTrcp2/HOS (Kumar et al.,
2007b) and produce inflammatory cytokines that stimulate
IFNAR1 ubiquitination and suppress IFN signaling (Huangfu
et al., 2012).
Here we report that ablation of Ifnar1 overcomes OIS in
BrafV600E-expressing melanocytes, leading to development of
aggressive metastatic melanomas. The re-expression of IFNAR1
in melanoma cells derived from these tumors restores the
expression of senescence markers and slows tumor growth;
this result is consistent with a cell-autonomous tumor-sup-
pressive role of IFN. However, data from human patients and a
syngeneic mouse transplanted model also strongly support an
indirect role of IFN in preventingmelanoma development. Finally,
mice harboring the knockin Ifnar1S526A alleles (Ifnar1SA that ex-
presses the ubiquitination-deficient IFNAR1SA mutant protein)
displayed a notably delayed melanomagenesis in the BrafV600E;
PtenD/D model. This retarded melanoma development was con-
current with decreased levels of Ifnar1SA protein and mRNA in
mouse skin and was characterized by dramatically suppressed
metastatic disease and increased responsiveness tomolecularly
targeted therapy or immunotherapy. These data characterize
IFN signaling as a tumor-suppressive pathway in melanoma172 Cell Reports 15, 171–180, April 5, 2016and provide the foundation for targeting IFNAR1 downregulation
to improve therapeutic outcomes.
RESULTS
Suppression of IFN Signaling Is Sufficient to Overcome
OIS and Promote Melanoma Development upon Braf
Activation
Human diploid fibroblasts transduced with oncogenic H-RasG12V
mutant exhibited an activated MAPK pathway and upregulated
levels of senescence protein markers (p21CIP1/WAF1 and HP1b)
and IFN-inducible IRF7 protein (Figure 1A). Concurrent knock-
down of IFNAR1 did not alter ERK phosphorylation but robustly
attenuated IRF7, p21CIP1/WAF1, and HP1b induction, suggesting
a role for IFN in onset of OIS. IFNAR1 knockdown also abro-
gated H-RasG12V-induced senescence-associated b-galactosi-
dase (SA-b-gal) activity (Figure 1B). In addition, knockout of Ifnar1
or neutralization of endogenous IFN attenuated senescence
induced by H-RasG12V mutant in mouse fibroblasts (Figures S1A
and S1B). These data suggest that IFNs contribute to OIS in vitro.
Constitutively active BrafV600E mutation frequently found in
atypical but non-malignant melanocytic lesions (dysplastic
nevi) was previously shown to induce senescence in vitro (Waja-
peyee et al., 2008) and to stimulate OIS in mouse melanocytes
(Damsky et al., 2015; Dankort et al., 2009; Ferguson et al.,
2015). We used this inducible mouse model (Tyr-CreERT2;
BrafCA/+), in which melanocytes express BrafV600E allele (Fig-
ure S1C) and activate the MAPK pathway (Figure 1C) upon
topical skin treatment with 4-hydroxytamoxifen (4HT). This treat-
ment upregulated the expression of mRNA for senescence
marker Cdkn1a and inflammatory cytokines (Tnfa, Il6, Ifng; Fig-
ure S1D) known to contribute to the senescence-associated
secretome (Freund et al., 2010). Activation of Braf also increased
p21CIP1/WAF1 protein (Figure 1C), as well as accumulation of
DNA-damage-associated 53BP1 foci and SA-b-gal-positive
cells (Figure 1D) characteristic of senescence. Given that all
these changes were dramatically attenuated by ablation of Ifnar1
(Figures 1C, 1D, and S1D), it is likely that IFN plays an important
role in melanocytes OIS in vivo.
BrafV600E; Ifnar1/ mice displayed a greater cell proliferation
as judged from Ki67 analysis in the skin and the appearance of
pigment globules suggestive of melanocytes abundance (SA-
b-gal staining; Figure 1D). Histological analysis of these sam-
ples reflected a massive hyperproliferation of melanocytes
(Figure S1E) that macroscopically resulted in notable skin
pigmentation (Figure 1E). These data suggest that IFN signaling
mediates cell senescence and restricts proliferation of melano-
cytes harboring activated Braf.
We continued to observe the cohorts of BrafV600E; Ifnar1+/+
and BrafV600E; Ifnar1/ mice over 14 months after 4HT treat-
ment. Consistent with a previous report (Dankort et al., 2009),
BrafV600E; Ifnar1+/+ mice developed few melanomas during this
time frame. Conversely, all BrafV600E; Ifnar1/ mice had devel-
oped tumor lesions (Figure 2A) that exhibited histopathological
characteristics of melanoma (Figure 2B). Melanoma develop-
ment in Ifnar1-deficient mice occurred with 100% penetrance
(Figure 2C). Upon development, aggressively growing tumor le-
sions significantly shortened the lifespan of these animals
Figure 1. IFNs Contribute to the OIS and
Restrict Proliferation in Melanocytes that
Harbor Activated Braf
(A) Immunoblot analysis of human diploid fibroblast
(HDF) IMR90 cells stably expressing shCON or
shIFNAR1 and transduced with control vector or
vector expressing H-RasG12V. Cell lysates were
prepared 5 days after transduction. Levels of
markers of senescence (HP1b, p21) and IFN
signaling (IRF7) were analyzed; total ERK levels
were used as a loading control.
(B) Representative SA-b-gal staining of IMR90
stably expressing shCON or shIFNAR1 and trans-
duced with control vector or vector expressing
H-Ras 5 days after transduction (left panel). Quan-
tification of the number of SA-b-gal-positive cells
per field (right panel).
(C) Immunoblot analysis of IFNAR1 from the whole
skin lysates of adult mice at day 30 after topical
administration of 4HT is shown. Levels of phospho-
ERK (to indicate activation of BRAF) are also
shown. Levels of total ERK and b-actin in whole
lysates of corresponding samples were used for
loading control (lower panels). The expression of
senescent marker p21 was also evaluated.
(D) Representative immunofluorescent analysis
and quantification of 53BP1-positive foci and SA-
b-gal- and Ki67-positive cells in the skin of adult
mice of indicated genotypes at day 30 after topical
administration of 4HT. Scale bar represents
100 mm. At least 20 fields randomly chosen from
three independent experiments were quantified.
(E) Representative images of the appearance of the
snout and ear and the underside of the lateral skin
from adult mice of indicated genotypes at day 30
after topical administration of 4HT.
Data are shown asmean ± SD; *p < 0.05; **p < 0.01;
***p < 0.001. Scale bar represents 100 mm. At
least 20 fields randomly chosen from three inde-
pendent experiments were quantified. See also
Figure S1.(Figure 2C) and were accompanied by numerous metastatic le-
sions in lymph nodes and lungs (Figures 2A and 2D). Similar re-
sults with yet shorter latency were obtained in Ifnar1-null animals
harboring two copies of activated BrafV600E (Figure S2). These
results indicate that inactivation of IFN signaling is sufficient for
Braf-driven melanomagenesis.
IFN Prevents Melanoma Development and Progression
viaCell-Autonomous andNon-autonomousMechanisms
Animals harboringBrafV600E; Ifnar1/ alleles lacked IFN signaling
in all tissues. To determine whether the protective role of IFN
against melanoma development is cell-autonomous and/or de-
pends on effects of IFN in cell types other than melanocytes, we
established a cell line called PVMM (Penn Vet mouse melanoma)
from a spontaneous skin lesion. These cells grew in vitro and
were characterized by constitutively hyperactive MAPK signaling
(which was sensitive to vemurafenib treatment) and lack of
IFNAR1 expression (Figure S3A). Furthermore, subcutaneous
(s.c.) transplantation of these cells into the flank of syngeneic
mice led to development of melanoma tumors that grew aggres-
sively and metastasized into the lungs (Figure S3B).We sought to determine the cell-autonomous effects of
IFN signaling by restoring IFNAR1 expression selectively in
melanoma cells. Given that hyperactive BRAF accelerates the
ubiquitination-driven downregulation of IFNAR1 (Kumar et al.,
2007b), we chose to use Ifnar1SA, which cannot undergo the
phosphorylation required for interacting with bTrcp2/HOS E3
ubiquitin ligase and subsequent ubiquitination, endocytosis,
and degradation of IFNAR1 (Kumar et al., 2003, 2004, 2007a).
PVMMcells were transducedwith vectors expressing GFP alone
or GFP with Ifnar1SA (Figure S3C). Compared with expression of
GFP alone, delivery of the ubiquitination-deficient IFNAR1 did
not affect MAPK activation yet led to upregulation of IRF7 and
p21 proteins (Figure 3A), increased number of SA-b-gal-positive
cells when grown in vitro or in vivo (Figure 3B), and in the latter
settings, retarded growth of tumors in syngeneic mice (Fig-
ure 3C). These results suggest that restoration of the cell-auton-
omous IFN signaling in melanoma cells can trigger senescence
and attenuate melanoma progression.
However, analysis of melanoma samples harvested from
patients before treatment with high-dose IFN adjuvant therapy
showed only a trend linking low IFNAR1 levels with clinicalCell Reports 15, 171–180, April 5, 2016 173
Figure 2. Suppression of IFN Signaling Is
Sufficient for BrafV600E-Driven Melanoma
Development
(A) Macroscopic appearance of tumor lesions and
sentinel lymph nodes developing in 4HT-treated
BrafCA/+; Ifnar1/ mice.
(B) H&E staining of ear (left panel) and lesions
(middle panel) and immunohistochemistry staining
of S100 in the lesions (right panel) from BrafV600E;
Ifnar1/ mice. Scale bar represents 100 mm.
(C) Incidence of malignant melanomas (left panel)
and Kaplan-Meier analysis of survival (right panel) of
mice of indicated genotypes at the indicated time
after 4HT treatment.
(D) H&E staining of lymph node and lung tissues
from BrafV600E; Ifnar1/ mice.
Scale bar represents 100 mm. See also Figure S2.outcomes of relapse or mortality of these patients (Figure 3D).
This trend did not reach statistical significance, suggesting that
the status of IFNAR1 in the benign tissues may also contribute
to the role of IFN signaling in melanoma progression. To corrob-
orate this possibility, we transplanted unmodified Ifnar1-null
PVMM tumor cells into syngeneic mice that harbored either
wild-type Ifnar1 or the knockin ubiquitination-deficient Ifnar1SA
allele (described in Bhattacharya et al., 2014).
PVMM developed noticeably smaller tumors (Figure 3E) and
did not produce lungmetastases in Ifnar1SAmice. A similar result
was obtained in thesemice inoculatedwith Ifnar1+/+ YUMM (Yale
University mouse melanoma) cells (Figure 3F). Moreover, YUMM
cells grew faster in Ifnar1/mice, further supporting the impor-
tance of IFN signaling in the stroma. Finally, a similar growth
delay in C3H/Hej Ifnar1SA mice was observed for syngeneic
SW1 mouse melanoma tumors (Figure S3D). In all, these results
suggest that IFNs counteract melanoma development and
progression through both cell-autonomous and non-cell-auton-
omous mechanisms.
Suppression of the IFN Pathway beyond a Specific
Threshold Promotes Melanoma Development,
Progression, and Metastasis and Decreases the
Efficacy of Molecularly Targeted Treatment and
Immunotherapy
Decreased levels of IFNAR1 were observed in human mela-
nomas compared to normal melanocytes frommatched patients
samples (Huangfu et al., 2012). Accelerated degradation of
IFNAR1 and attenuation of IFN responses can be promoted by174 Cell Reports 15, 171–180, April 5, 2016the stimuli associated with tumor develop-
ment, including unfolded protein response
(Bhattacharya et al., 2010, 2011; Liu et al.,
2009), integrated stress (Bhattacharya
et al., 2013), vascular endothelial growth
factor (Zheng et al., 2011a), and inflamma-
tion (Bhattacharya et al., 2014; Huangfu
et al., 2012; Qian et al., 2011). Given
that accelerated degradation of IFNAR1
induced by oncogene and/or inflammation
or tumor stress in both melanocytes andstromal cells may mask the importance of this receptor in mela-
noma development and progression, we sought to test the role
of IFN signaling using a combination of the Ifnar1SA allele with
the powerful inducible Tyr-CreERT2; BrafCA/+; Ptenf/f mouse
model that combines melanocyte-specific activation of Braf
with ablation of Pten (Figure S4A) and ensuing activation of
PI3K-Akt pathway (Damsky et al., 2011; Dankort et al., 2009).
Concurrent activation of Braf and PI3K-Akt pathways led to a
noticeable decrease in IFNAR1 levels in the skin of Ifnar1+/+
mice; a lesser downregulation was observed in Ifnar1SA tissues
(Figure S4B). Accordingly, both gene array expression and
qPCR analyses demonstrated suppressed IFN signaling signa-
tures in the skin of Ifnar1+/+ animals compared to Ifnar1SA skin
(Figures S4C and S4D). Expression of BrafV600E alleles, along
with Pten inactivation, in Ifnar1+/+ mice led to a rapid develop-
ment of aggressive metastatic melanomas within 20 days of
tamoxifen treatment (Figures 4A–4D). At this time point, the
analogous Ifnar1SA skin tissues displayed increased numbers
of SA-b-gal-positive cells (Figure 4B) and only mild melanocyte
proliferation, without any sign of melanoma development or
metastatic spread. Melanomas in Ifnar1SA mice developed later
(Figures 4A–4D). Similar data were obtained in mice harboring a
single copy of activated Braf (Figures S4E and S4F). These
results suggest that development of melanoma is delayed in
animals that maintain a higher level of IFN signaling. Conversely,
downregulation of IFNAR1 and suppression of IFN responses in
wild-type mice may accelerate development of melanoma.
The melanoma-induced mortality was also delayed in Ifnar1SA
mice (Figure 4E). This mortality was associated with the primary
Figure 3. IFNs Prevent Melanoma Develop-
ment and Progression via Cell-Autonomous
and Non-autonomous Mechanisms
(A) Immunoblot analysis of indicated proteins in
lysates from parental (P) PVMM cells and de-
rivatives (transduced for expressing GFP alone or
with IFNAR1SA) 4 days after transduction.
(B) SA-b-gal staining (blue) and percentage of
SA-b-gal-positive PVMM cells and their derivatives
described in (A). Cells were grown in vitro (upper
panels) or injected to form tumors (lower panels,
counterstained with fast red). Data are shown as
mean ± SD from three independent experiments (at
least 30 randomly chosen fields per experiment).
(C) Tumor growth curves of PVMM cells (P) and
their derivatives expressing GFP (GFP) or GFP with
IFNAR1SA mutant (IFNAR1SA) after s.c. injection of
13 106 cells into Ifnar1+/+mice. Similar results were
obtained in at least two additional independent
experiments.
(D) Fisher’s exact test analysis of relationship
between IFNAR1 levels (analyzed by immunohis-
tochemistry in samples harvested from melanoma
patients before treatment with high-dose IFN) and
therapy outcome.
(E) PVMM tumor growth in Ifnar1+/+ (blue) or
Ifnar1SA (red) mice after s.c. injection of 1 3 106
PVMM cells. Similar results were obtained in at
least two additional independent experiments.
(F) Average tumor growth of YUMM in Ifnar1+/+
(blue), Ifnar1SA (red), or Ifnar1/ (black) mice after
s.c. injection of 13 106 YUMM cells. Similar results
were obtained in at least two additional indepen-
dent experiments.
*p < 0.05. Scale bar represents 100 mm. See also
Figure S3.tumor load and tumor size that approached the limits of hu-
mane experimentation. While this tumor burden in euthanized
animals was identical in Ifnar1+/+ animals (day 20 after tamox-
ifen treatment) and in Ifnar1SA mice (day 60 after tamoxifen
treatment), it is critical that the latter animals lacked distant
metastases (Figure 4D). Furthermore, despite a substantial
primary tumor growth, Ifnar1SA mice displayed a significantly
reduced number of local lymph node metastases (Figure 4F).
These results suggest that IFN signaling is even more critical
for suppressing the metastatic disease than for inhibiting pri-
mary melanoma growth.
To delineate the mechanisms of melanoma development in
Ifnar1SA mice, we compared skin from these animals obtained
20 and 60 days after tamoxifen treatment by global gene expres-
sion analysis. A notable suppression of expression of IFN-induc-
ible genes was observed at the latter time point (Figures 5A and
S5). Subsequent qPCR analysis of expression of Ifnb and indi-
vidual IFN-stimulated genes also revealed that IFN signaling is
suppressed in the skin of BrafVE, PtenD/D, Ifnar1+/+ type mice
within 20 days (Figure 5B). However, in Ifnar1SA at day 20, the
levels of expression of Ifnb, Isg15, and Irf7 mice were still sub-
stantially higher than those in Ifnar1+/+ animals. At this time, a
spike in Ifnb expression corresponding to increase in IRF7 and
p21 proteins (Figure 5C), consistent with increased SA-b-gal
staining (Figure 4B), was observed, further suggesting the impor-
tance of IFN signaling in melanocyte senescence.Expression of IFN-inducible genes continued to decline by
the time of melanoma development in Ifnar1SA mice at day 60
(Figure 5B). Expression of IRF7 and p21 proteins followed similar
kinetics (Figure 5C). These results indicate a putative link be-
tween levels of IFN signaling and melanoma development.
This decrease in IRF7 and p21CIP1/WAF1 levels at day 60 in
Ifnar1SA skins coincided with a notable downregulation of the
levels of IFNAR1 protein and mRNA that nearly reached those
observed in animals harboring wild-type Ifnar1 (Figure 5C).
These results indicate an activation of additional mechanisms
that act to downregulate the ubiquitination-deficient IFNAR1SA
protein. In all, these data support a concept that such addi-
tional mechanisms are aimed at decreasing IFN signaling
beyond the threshold that is capable of preventing melanoma-
genesis. Accordingly, efficient inactivation of IFN signaling in
the skin appears to be important for melanoma development
and progression.
In lieu of data pointing to the importance of IFN signaling in
non-melanocytic tissues (Figure 3), we sought to determine
whether degradation of IFNAR1 plays a role in regulating the
sensitivity of melanoma to molecular or immunotherapy. To
this end, we initiated melanoma development by topical appli-
cation of 4HT onto the skins of the Tyr-CreERT2; BrafCA/+;
Ptenf/f mice that harbored wild-type or mutant (Ifnar1SA) IFN
receptor. Upon reaching an approximately 50 mm2 tumor size,
which required on average 21 days for Ifnar1+/+ and 43 daysCell Reports 15, 171–180, April 5, 2016 175
Figure 4. Downregulation of the IFN Re-
ceptor Promotes Melanoma Development,
Progression, and Metastasis
(A) Macroscopic appearance of the sentinel lymph
nodes and tumor lesions on the ear and snout
from BrafCA; PtenD/D; Ifnar1+/+ and BrafCA; PtenD/D;
Ifnar1SAmice at day 20 and day 60 after generalized
induction of recombination by tamoxifen.
(B) SA-b-gal/fast red staining of skin tissues from
corresponding mice.
(C) H&E staining of the ear and skin tissues from
corresponding mice.
(D) H&E staining of organs from corresponding
mice. Metastatic lesions are indicated by arrows.
(E) Kaplan-Meier analysis of survival in animal co-
horts described in (A)–(C).
(F) Quantification of metastatic lesions in the lymph
node from mice of indicated genotypes. Data are
shown as mean ± SD (n = 5–6 per group); *p < 0.05.
Scale bar represents 100 mm. See also Figure S4.for Ifnar1SA animals, we started treatment of mice with either
BRAF inhibitor vemurafenib or anti-PD-1 antibody. The latter
treatment modestly retarded subsequent tumor growth in
Ifnar1+/+ mice but was significantly more efficacious in Ifnar1SA
animals (Figure 5D). Similarly, whereas melanomas harboring
wild-type IFN receptor responded to vemurafenib by merely
slowing tumor progression, at the least, stable disease was
observed in Ifnar1SA mice (Figure 5E). These results suggest
that downregulation of IFNAR1 limits the efficacy of both molec-
ular anti-tumor and immunomodulatory therapies formelanomas
that harbor activated Braf and inactivated Pten.
DISCUSSION
IFN Signaling as a Tumor-Suppressive Pathway in
Melanoma
The long reported suppressive effects of IFN on growth and
survival of established melanoma cells in vitro have been
used to provide a foundation for recombinant IFN therapies176 Cell Reports 15, 171–180, April 5, 2016(Bonnem and Spiegel, 1984; Fisher and
Grant, 1985; Kirkwood and Ernstoff,
1984, 1985; Sikora, 1980). However, the
concept of endogenous IFN signaling
as a tumor-suppressive pathway that in-
hibits melanoma development has been
underappreciated. Findings of suppres-
sion of the IFN pathway in melanoma
patients’ leukocytes (Critchley-Thorne
et al., 2007, 2009) and tumors, where it
inversely correlates with relapse-free
survival (Bald et al., 2014), link the
endogenous IFN pathway with mela-
noma progression. Here we provide an
animal model-based mechanistic link be-
tween endogenous IFN and inhibition of
melanomagenesis and demonstrate that
IFN signaling plays a tumor-suppressive
role in melanoma.Our work used genetically engineered and transplanted
mouse melanoma models to show that ablation of Ifnar1 over-
comes OIS, including melanocyte senescence induced by acti-
vated Braf (Figure 1). Furthermore, inactivation of IFN signaling
in this context is sufficient to promote the development of
aggressive metastatic melanomas (Figure 2). Whereas expres-
sion of IFNAR1SA in Ifnar1-null melanoma cells can induce
senescence and suppress melanoma growth in vivo, data from
human melanoma patients treated in the adjuvant setting
demonstrate that levels of IFNAR1 in melanoma cells do not
alone reliably predict clinical outcomes with high-dose IFN.
These findings suggest that IFNAR1 status in benign cells of
non-melanocytic origin plays an important role in tumor-sup-
pressive and anti-metastatic functions of endogenous IFN, in
addition to melanocytes OIS. These conclusions, supported by
results in transplantablemodels grown in Ifnar1SAmice (Figure 3),
are in line with the previously described role of IFN signaling in
immune responses against melanoma (Bald et al., 2014; Fuertes
et al., 2011). The putative role of IFNAR1-dependent restriction
Figure 5. Inactivation of the IFN Pathway
during Melanoma Development Decreases
the Efficacy of Melanoma Treatment
(A) Gene set enrichment analysis (Moserle IFN
response, left panel) and heatmap (right panel) of
IFNa/b signaling pathway genes of the tran-
scriptome profiles of the skin tissues from BrafCA;
PtenD/D; Ifnar1SA mice collected at day 20 and day
60 after tamoxifen treatment. NES, normalized
enrichment score; FDR, false discovery rate.
(B) qPCR analysis of the expression of IFN-stimu-
lated genes in skin tissues from mice of indicated
genotypes at day 20 and day 60 after tamoxifen
administration. Untreated mice of the same ge-
notypes were used as a control. Data are shown as
mean ± SD (n = 5–6 per group).
(C) Immunoblot analysis of indicated protein levels
in the skin tissues lysates from mice of indicated
genotypes treated as indicated (two samples per
group). The Ifnar1/ mice skin sample serves as
a negative control for IFNAR1 detection (analyzed
by immunoprecipitation-immunoblotting [IP-IB]).
Relative levels of Ifnar1 mRNA (compared with
untreated skin in Ifnar1+/+ animals) are shown
below the IFNAR1 protein panel.
(D) Relative local melanoma tumor volume change
in mice of indicated genotypes treated with control
or anti-PD-1 antibody. Tumors were induced by
topical application of 4HT. Tumor size in each of
the treatment groups was measured every other
day and plotted as the percentage change in tumor
size compared to the starting size (50 mm2). Data
are shown as mean ± SD (n = 5–6 per group).
(E) Relative local melanoma tumor volume change inmice treatedwith a vehicle control or vemurafenib (Vem). Tumorswere induced by topical application of 4HT.
Tumor size in each of the treatment groups was measured every other day and plotted as the percentage change in tumor size compared to the starting size
(50 mm2). Data are shown as mean ± SD (n = 5–6 per group).
*p < 0.05; **p < 0.01. See also Figure S5.of the inflammatory secretome (Figure S4D) in suppressing the
distant metastases in Ifnar1SA mice is under investigation.
Mechanisms of Inactivation of the IFN Pathway in
Melanoma
Alterations in the recruitment of dendritic cells (known for their
potent ability to produce IFN (Zitvogel et al., 2015) and lacking
in melanomas characterized by an activated b-catenin pathway
(Spranger et al., 2015) may affect overall expression of IFN
ligands in the tumors. Furthermore, results from experiments
that used the expression of IFNAR1SA mutant in vitro and in vivo
(Figures 3 and 4) suggest that specific serine phosphorylation-
dependent ubiquitination and degradation of IFNAR1 represents
an important mechanism underlying downregulation of IFNAR1
in transformed melanocytes and/or stromal cells during the
development of melanoma. While activation of Braf alone can
stimulate partial IFNAR1 downregulation (Figure 1A), additional
signaling pathways activated in developing melanoma are likely
to further eliminate IFNAR1, thereby depressing IFN signaling
beyond the threshold at which it can sustain the tumor-suppres-
sive role. Robust melanoma development in BrafV600Emice (Fig-
ure 2) upon complete ablation of IFNAR1 strongly supports this
hypothesis. Accordingly, a delay of melanoma development in
Ifnar1SA mice indicates that the ability of cells to maintain a
certain level of IFNAR1 expression (despite a decrease in Ifnar1mRNA; Figure 5C) is important for counteracting the effects of
oncogenic pathways and stimulation of melanoma development
and progression.
Furthermore, eventual development of melanoma in Ifnar1SA
mice coincides with a decrease in IFNAR1SA mRNA and protein
levels and expression of IFN-stimulated genes detected in
affected mouse skin (Figure 5). Because IFNAR1SA mutant
protein cannot interact with bTrcp2/HOS (Kumar et al., 2003,
2004), these findings indicate that activation of a yet-to-
be-characterized bTrcp2/HOS-independent pathway occurs in
malignant melanocytes and/or stromal cells to downregulate
the levels of IFNAR1 and suppress IFN signaling. A decrease
of Ifnar1mRNA levels seen in these tumors (Figure 5C) is indica-
tive of transcriptional suppression and/or accelerated Ifnar1
mRNA decay that can be a consequence of hyperactive MAPK
and PI3K signaling. Upregulation of histone methyltransferase
EZH2 and H3K27 methylation-driven suppression of several tu-
mor suppressor genes was found in BrafV600E-expressing mela-
nomas (Hou et al., 2012). Use of an EZH2 inhibitor GSK503
(capable of upregulating the levels of Ifnar1 in YUMM cells;
data not shown) was found to prevent metastatic disease in
the Tyr::N-RasQ61K, Ink4a/-driven mouse melanoma model
(Zingg et al., 2015)—a phenotype reminiscent of suppressed
metastatic spread in Ifnar1SA mice (Figure 4). In addition to the
mechanisms conferring a decrease in Ifnar1 mRNA, we cannotCell Reports 15, 171–180, April 5, 2016 177
rule out a role for bTrcp2/HOS-independent proteolysis of
IFNAR1 that may involve activation of extracellular proteases
previously shown to be upregulated in human and mouse mela-
nomas (Hofmann et al., 2000, 2005; Ramont et al., 2003).
Putative Therapeutic Importance of Re-activation of IFN
Signaling in Melanoma
Given that IFN therapy prevents relapse and death in up to 33%
of melanoma patients, there is a pressing need to identify means
to enhance this benefit and to stratifying melanoma patients
to apply this modality to those patients who can benefit most
from IFN treatment (Eggermont et al., 2014; Thompson et al.,
2009). While a number of parameters can be used as predictors
of response to IFN therapy (Gogas andKirkwood, 2009), our data
in melanoma patients suggest that relative IFNAR1 protein levels
in melanoma cells are unlikely to be sufficiently informative (Fig-
ure 3D). Given a demonstrated role of IFN signaling in the benign
cells of the tumor microenvironment (Figures 3E and 3F), and
potentially predictive value of IFN responses in peripheral blood
lymphocytes (Simons et al., 2011), future studies should focus on
defining IFNAR1 levels and other parameters of IFN signaling in
both melanoma and stromal cells.
Ifnar1SAmicemaintaining some degree of IFN signaling largely
suppressed distant metastases of PVMM or BrafV600E/PtenD/D
melanomas (Figure 4). Given that distant metastases ultimately
determine the survival of melanoma patients, these results sug-
gest that the benefit of IFN therapy may be found in its ability to
inhibit the process of metastatic dissemination. Conversely, the
presence of distant metastases points to evidence of de facto
inactivation of endogenous IFN pathway functions and predicts
limited survival benefits of pharmacological interventions with
IFN. This hypothesis is supported by clinical data from several
available reports (Eggermont et al., 2014; Gogas and Kirkwood,
2009; Kirkwood et al., 2012; Tarhini et al., 2012; Thompson et al.,
2009).
Additional data suggest that preserving at least some IFN
signaling can be beneficial because it increases the responsive-
ness to BRAF inhibitors and immunotherapy (Figures 4 and 5).
The latter results are in line with data reported in a different mel-
anoma model, in which administration of IFN inducers improved
the effect of immune checkpoint inhibitors (Bald et al., 2014).
Efforts aimed at stabilization of IFNAR1 (via use of inhibitors of
kinases involved in its phosphorylation or of SCF-bTrcp2/HOS li-
gases such as MLN4924) alone or in combination with agents
increasing the levels of Ifnar1mRNA will be undertaken in future
studies.
EXPERIMENTAL PROCEDURES
Melanoma Patients’ Samples and Analysis
Melanoma patients with primary and/or nodal tumors banked at the University
of Pittsburgh Cancer Institute (UPCI) under tissue/blood biomarker protocol
UPCI 96-099 were retrieved. The detailed patient information is provided in
Table S1.
Mice
All experiments with animals were carried out under protocol 803995
approved by the Institutional Animal Care andUse Committee of the University
of Pennsylvania. Mice were maintained in a specific pathogen-free facility in178 Cell Reports 15, 171–180, April 5, 2016accordance with American Association for Laboratory Animal Science guide-
lines. All mice had water ad libitum and were fed regular chow.
C57BL/6 (Ifnar1+/+, Ifnar1SA, or Ifnar1/; Bhattacharya et al., 2014) and
BrafCA, Tyr-CreERT2; and BrafCA, Tyr-CreERT2, Ptenf/f mice were previously
described (Dankort et al., 2009). These mice were crossed to obtain needed
genotypes, and the littermates differing in their Ifnar1 status were used for
experiments. C3H/Hej Ifnar1+/+ mice were purchased from Jackson Labora-
tory and crossed with C57BL/6 Ifnar1SA for at least ten generations to obtain
the C3H/Hej littermates (Ifnar1SA or Ifnar1+/+) that were used in experiments
on the SW1 melanoma cell line.
Topical administration of 4HT of BrafCA; Tyr-CreERT2; Ifnar1/ or BrafCA;
Tyr-CreERT2; Ifnar1+/+ mice was performed by preparing a 25–50 mg/ml
(65–130 mM) solution of 4HT (70% Z-isomer; Sigma-Aldrich) in dimethylsulph-
oxide and applying enough solution to wet the right ear, right flank, and tail
with a small paintbrush on postnatal days 2, 3, and 4.
For localized melanoma induction, adult (6–8 weeks of age) BrafCA,
Tyr-CreERT2, Ptenf/f, Ifnar1SA or BrafCA, Tyr-CreERT2, Ptenf/f, Ifnar1+/+ mice
were treated topically with 1–2 ml of 1.9 mg/ml (5 mM) 4HT on the back skin.
Generalized induction in adult BrafCA, Tyr-CreERT2, Ptenf/f, Ifnar1SA or BrafCA,
Tyr-CreERT2, Ptenf/f, Ifnar1+/+ mice was performed by intraperitoneal injection
of 25 mg/kg tamoxifen on three consecutive days. In this case, tamoxifen was
prepared as a 10 mg/ml suspension in peanut oil.
Cell Lines, Culture Conditions, and Viral Infection
BrafCA; Ptennull; Cdkn2anull (YUMM, a gift from M. Bosenberg and A. Weerar-
atna), SW1, 293T (provided by Z. Ronai, The Burnham Institute), and BrafCA;
Tyr-CreERT2; Ifnar1/ (PVMM) cell lines and normal human fibroblasts
(IMR90) stably expressing control shRNA (shCON) or shRNA against IFNAR1
(shIFNAR1) were maintained at 37C with 5% CO2 in DMEM supplemented
with 10% heat-inactivated fetal calf serum, penicillin, streptomycin, and
L-glutamine. For lentiviral transduction, 293T cells were transfected with
pCIG plasmids encoding EGFP or mouse ubiquitination-deficient IFNAR1SA
mutant, together with EGFP (described in Huangfu et al., 2012) using Lipofect-
amine Plus (Invitrogen). After 24–48 hr, supernatants were passed through
a 0.45 mm nylon filter, mixed with Polybrene (8 mg/ml; Santa Cruz), and
transferred to plated cancer cells. Transduction efficiency was verified by
fluorescence-activated cell sorting analysis and usually was more than 80%.
Similarly, 293T cell producing empty virus or virus expressingH-RasG12V onco-
gene were used for retroviral transduction of IMR90 cells.
Cancer Cell Transplantation and Organ Harvest
Cancer cells were inoculated subcutaneously in the right flank at 13 106 cells,
100 ml Dulbecco’s phosphate-buffered saline (DPBS). Tumors were measured
by caliper, and size was calculated as (length 3 width). Mice were euthanized
when the tumor reached 250–300 mm2, and tumors were dissected and
analyzed.
Immunofluorescence and Immunohistochemistry
Skin samples harvested from mice were frozen in Tissue-Tek O.C.T. com-
pound and cryosectioned in Leica CM3050 S Cryostats, fixed in acetone,
washed and blocked with PBS containing 5% goat serum, and incubated
with primary antibody against 53BP1 (A300-272A; Bethyl Laboratories) or
anti-IFNAR1 antibody (Sino Biologicals). Levels of human IFNAR1 in mela-
noma cells were determined by immunohistochemistry as previously
described (Huangfu et al., 2012) and the stainingwas scored by a qualified der-
matopathologist in a double-blind manner.
Melanoma Treatment
When the tumors reached 50 mm2, animals were gavaged daily with 40 mg/kg
vemurafenib (PLX4032, S1267; Selleckchem) in 2% hydroxypropylcellulose
(Klucel). For the PD-1 blockade experiment, 100 mg anti-PD-1 (RMP1-14;
BioyXCell) or control Ab (2A3; BioXCell) were administered intraperitoneally
to mice every 4 days starting at day 8 for a total of six times.
Microarray Analyses with Illumina Whole-Genome Arrays
Total RNA was isolated with the miRNeasy mini kit (QIAGEN) from skin or
tumor samples of BrafCA, Tyr-CreERT2, Ptenf/f, Ifnar1SA mice at day 20 and
day 60 after generalized induction with tamoxifen. Biotin-labeled cRNA prep-
arations were obtained using the TargetAmp-Nano Labeling Kit (Epicenter) as
recommended by the manufacturer. Thereafter, 0.75 mg cRNA was hybridized
to Illumina Sentrix Mouse-6 v.1 BeadChips, which were scanned with an Illu-
mina BeadStation 500 (both from Applied Biosystems). Data were collected
with Illumina BeadStudio 3.1.1.0 software, and statistical analyses were con-
ducted on the IlluminaGUI R-package. Gene sets from microarray data were
analyzed for overlap with curated datasets (C5, H) in MSigDB using the web
interface available at http://www.broadinstitute.org/gsea/msigdb.
Statistical Analyses
Data are presented as mean ± SD. Statistical analysis was performed using
Microsoft Excel. Statistical significance was calculated using a two-tailed
Student’s t test. A p value < 0.05 was considered significant.
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